SIR-Spheres® Y-90 resin microspheres are approved and indicated in over 40 countries for the treatment of patients with inoperable liver tumours. In addition to its use in metastatic colorectal cancer and hepatocellular carcinoma, a broad range of clinical experience has been gained from patients with liver metastases from neuroendocrine tumours, breast cancer, ocular melanoma and pancreatic cancer, as well as in cholangiocarcinoma.

In the latter, a large international study, called SIRCCA, is evaluating the benefit of applying SIR-Spheres Y-90 resin microspheres prior to systemic chemotherapy. The combination could become a new treatment option for patients with unresectable intrahepatic cholangiocarcinoma (ICC).

Sirtex is broadening its focus to examine the use of SIR-Spheres Y-90 resin microspheres in a number of cancers outside the liver. The first of these studies, called RESIRT, investigated its potential benefit in the treatment of primary renal cell cancer.

de Souza P, Aslan P et al.  Phase 1 study of selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres in patients (pts) with renal cell carcinoma (RCC): RESIRT.  ESMO Congress, Annals of Oncology 2016; 27 (Suppl 6) Abs: P-803.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.